Abstract
Background: Inhalation therapy is one of the cornerstones of the daily treatment regimen in patients with cystic fibrosis (CF). Recommendations regarding the addition of bronchodilators, especially salbutamol are conflicting due to the lack of evidence. New diagnostic measures such as multiple-breath washout (MBW) and functional magnetic resonance imaging (MRI) have the potential to reveal new insights into bronchodilator effects in patients with CF. Objective: The objective of the study was to comprehensively assess the functional response to nebulized inhalation with salbutamol in children with CF. Methods: Thirty children aged 6–18 years with stable CF performed pulmonary function tests, MBW, and matrix pencil-MRI before and after standardized nebulized inhalation of salbutamol. Results: Lung clearance index decreased (improved) by −0.24 turnover (95% confidence interval [CI]: −0.53 to 0.06; p = 0.111). Percentage of the lung volume with impaired fractional ventilation and relative perfusion decreased (improved) by −0.79% (CI: −1.99 to 0.42; p = 0.194) and −1.31% (CI: −2.28 to −0.35; p = 0.009), respectively. Forced expiratory volume (FEV1) increased (improved) by 0.41 z-score (CI: 0.24–0.58; p < 0.0001). We could not identify specific clinical factors associated with a more pronounced effect of salbutamol. Conclusions: There is a positive short-term effect of bronchodilator inhalation on FEV1 in patients with CF, which is independent of ventilation inhomogeneity. Heterogeneous response between patients suggests that for prediction of a therapeutic effect this should be tested by spirometry in every patient individually.
References
1.
O’Sullivan
BP
, Freedman
SD
. Cystic fibrosis
. Lancet
. 2009
;373
(9678
):1891
–904
. .2.
Kerem
E
, Reisman
J
, Corey
M
, Canny
GJ
, Levison
H
. Prediction of mortality in patients with cystic fibrosis
. N Engl J Med
. 1992
;326
(18
):1187
–91
. .3.
Castellani
C
, Duff
AJA
, Bell
SC
, Heijerman
HGM
, Munck
A
, Ratjen
F
, ECFS best practice guidelines: the 2018 revision
. J Cyst Fibros
. 2018
;17
(2
):153
–78
. .4.
Flume
PA
, O’Sullivan
BP
, Robinson
KA
, Goss
CH
, Mogayzel
PJ
, Willey-Courand
DB
, Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health
. Am J Respir Crit Care Med
. 2007
;176
(10
):957
–69
. .5.
Mogayzel
PJ
, Naureckas
ET
, Robinson
KA
, Mueller
G
, Hadjiliadis
D
, Hoag
JB
, Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health
. Am J Respir Crit Care Med
. 2013
;187
(7
):680
–9
. .6.
Wark
P
, McDonald
VM
. Nebulised hypertonic saline for cystic fibrosis
. Cochrane Database Syst Rev
. 2018
;9
(9
):CD001506
. .7.
Brand
PL
. Bronchodilators in cystic fibrosis
. J R Soc Med
. 2000
;93
(Suppl 38
):37
–9
.8.
Cropp
GJ
. Effectiveness of bronchodilators in cystic fibrosis
. Am J Med
. 1996
;100
(1A
):19S
–29S
. .9.
Halfhide
C
, Evans
HJ
, Couriel
J
. Inhaled bronchodilators for cystic fibrosis
. Cochrane Database Syst Rev
. 2005
(4
):CD003428
. .10.
Bennett
WD
. Effect of beta-adrenergic agonists on mucociliary clearance
. J Allergy Clin Immunol
. 2002
;110
(Suppl 6
):S291
–7
. .11.
Barry
PJ
, Flume
PA
. Bronchodilators in cystic fibrosis: a critical analysis
. Expert Rev Respir Med
. 2017
;11
(1
):13
–20
. .12.
Robinson
PD
, Latzin
P
, Verbanck
S
, Hall
GL
, Horsley
A
, Gappa
M
, Consensus statement for inert gas washout measurement using multiple- and single- breath tests
. Eur Respir J
. 2013
;41
(3
):507
–22
. .13.
Nyilas
S
, Bauman
G
, Sommer
G
, Stranzinger
E
, Pusterla
O
, Frey
U
, Novel magnetic resonance technique for functional imaging of cystic fibrosis lung disease
. Eur Respir J
. 2017
;50
(6
):1701464
. .14.
Eber
E
, Oberwaldner
B
, Zach
MS
. Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effect of theophylline and sympathomimetics
. Pediatr Pulmonol
. 1988
;4
(4
):205
–12
. .15.
Hordvik
NL
, König
P
, Morris
D
, Kreutz
C
, Barbero
GJ
. A longitudinal study of bronchodilator responsiveness in cystic fibrosis
. Am Rev Respir Dis
. 1985
;131
(6
):889
–93
. .16.
Kattan
M
, Mansell
A
, Levison
H
, Corey
M
, Krastins
IR
. Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis
. Thorax
. 1980
;35
(7
):531
–5
. .17.
König
P
, Gayer
D
, Barbero
GJ
, Shaffer
J
. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report
. Pediatr Pulmonol
. 1995
;20
(4
):205
–14
. .18.
Farrell
PM
, White
TB
, Ren
CL
, Hempstead
SE
, Accurso
F
, Derichs
N
, Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation
. J Pediatr
. 2017
;181S
:S4
–15.e1
. .19.
Frauchiger
BS
, Carlens
J
, Herger
A
, Moeller
A
, Latzin
P
, Ramsey
KA
. Multiple breath washout quality control in the clinical setting
. Pediatr Pulmonol
. 2021
;56
(1
):105
–12
. .20.
Miller
MR
, Hankinson
J
, Brusasco
V
, Burgos
F
, Casaburi
R
, Coates
A
, Standardisation of spirometry
. Eur Respir J
. 2005
;26
(2
):319
–38
. .21.
Bauman
G
, Pusterla
O
, Bieri
O
. Ultra-fast steady-state free precession pulse sequence for Fourier decomposition pulmonary MRI
. Magn Reson Med
. 2016
;75
(4
):1647
–53
. .22.
Willers
C
, Bauman
G
, Andermatt
S
, Santini
F
, Sandkühler
R
, Ramsey
KA
, The impact of segmentation on whole-lung functional MRI quantification: repeatability and reproducibility from multiple human observers and an artificial neural network
. Magn Reson Med
. 2021
;85
(2
):1079
–92
. .23.
Bauman
G
, Bieri
O
. Matrix pencil decomposition of time-resolved proton MRI for robust and improved assessment of pulmonary ventilation and perfusion
. Magn Reson Med
. 2017
;77
(1
):336
–42
. .24.
Anagnostopoulou
P
, Latzin
P
, Jensen
R
, Stahl
M
, Harper
A
, Yammine
S
, Normative data for multiple breath washout outcomes in school-aged Caucasian children
. Eur Respir J
. 2020
;55
(4
):1901302
. .25.
Nyilas
S
, Bauman
G
, Pusterla
O
, Ramsey
K
, Singer
F
, Stranzinger
E
, Ventilation and perfusion assessed by functional MRI in children with CF: reproducibility in comparison to lung function
. J Cyst Fibros
. 2019
;18
(4
):543
–50
. .26.
Quanjer
PH
, Stanojevic
S
, Cole
TJ
, Baur
X
, Hall
GL
, Culver
BH
, Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
. Eur Respir J
. 2012
;40
(6
):1324
–43
.27.
Koopman
M
, Zanen
P
, Kruitwagen
CL
, van der Ent
CK
, Arets
HG
. Reference values for paediatric pulmonary function testing: the Utrecht dataset
. Respir Med
. 2011
;105
(1
):15
–23
. .28.
Hordvik
NL
, Sammut
PH
, Judy
CG
, Strizek
SJ
, Colombo
JL
. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis
. Am J Respir Crit Care Med
. 1996
;154
(1
):156
–60
. .29.
Abbas
C
, Singer
F
, Yammine
S
, Casaulta
C
, Latzin
P
. Treatment response of airway clearance assessed by single-breath washout in children with cystic fibrosis
. J Cyst Fibros
. 2013
;12
(6
):567
–74
. .30.
Roethlisberger
K
, Nyilas
S
, Riedel
T
, Wolfensberger
J
, Singer
F
, Latzin
P
. Short-term effects of elastic chest wall restriction on pulmonary function in children with cystic fibrosis
. Respiration
. 2018
;96
(6
):535
–42
. .31.
Bland
JM
, Altman
DG
. Applying the right statistics: analyses of measurement studies
. Ultrasound Obstet Gynecol
. 2003
;22
(1
):85
–93
. .32.
Gustafsson
PM
. Peripheral airway involvement in CF and asthma compared by inert gas washout
. Pediatr Pulmonol
. 2007
;42
(2
):168
–76
. .33.
Abbas
C
, Singer
F
, Yammine
S
, Casaulta
C
, Latzin
P
. Treatment response of airway clearance assessed by single-breath washout in children with cystic fibrosis
. J Cyst Fibros
. 2013
;12
(6
):567
–74
. .34.
Mentore
K
, Froh
DK
, de Lange
EE
, Brookeman
JR
, Paget-Brown
AO
, Altes
TA
, Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment1
. Acad Radiol
. 2005
;12
(11
):1423
–9
.35.
Borghardt
JM
, Kloft
C
, Sharma
A
. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes
. Can Respir J
. 2018
;2018
:2732017
. .36.
Spiekerkoetter
E
, Fabel
H
, Hoeper
MM
. Effects of inhaled salbutamol in primary pulmonary hypertension
. Eur Respir J
. 2002
;20
(3
):524
–8
. .37.
Ballester
E
, Reyes
A
, Roca
J
, Guitart
R
, Wagner
PD
, Rodriguez-Roisin
R
. Ventilation-perfusion mismatching in acute severe asthma: effects of salbutamol and 100% oxygen
. Thorax
. 1989
;44
(4
):258
–67
. .38.
Polverino
E
, Gómez
FP
, Manrique
H
, Soler
N
, Roca
J
, Barberà
JA
, Gas exchange response to short-acting beta2-agonists in chronic obstructive pulmonary disease severe exacerbations
. Am J Respir Crit Care Med
. 2007
;176
(4
):350
–5
. .39.
BTS/SIGN
. British guideline on the management of asthma
. Thorax
. 2014
;69
(Suppl 1
):1
–192
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
